Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Authors: Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI Abstract Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this disease present as non-muscle-invasive bladder cancer (NMIBC), with cancer recurrence or progression to muscle-invasive cancer in more than 50% of patients after initial therapy. NMIBC is an immune-responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. More recently, immunotherapy has seen much progress in a variety of cancers, includin...
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
We present preclinical evidence of interaction between these pathways and the rationale for combined blockade. Beyond well-known effects on pathologic angiogenesis, VEGF blockade also may decrease immune tolerance and enhance PD-1/PD-L1 blockade. We conclude with the results of several early trials of combined VEGF and PD-1/PD-L1 blockade, which demonstrate encouraging antitumor activity, and we pose questions for future study. PMID: 28749908 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Yes, treatment for CML should continue indefinitely.
Authors: Short NJ, Jabbour E PMID: 28749909 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

No, treatment for CML should not continue indefinitely.
Authors: Etienne G, Mahon FX PMID: 28749910 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: ASCO cage match: BR vs R-CHOP.
Authors: Kahl BS PMID: 28749911 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Which patients with early-stage triple-negative breast cancer should receive a platinum?
Authors: Sikov WM PMID: 28749912 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New insights into cytomegalovirus infection after allogeneic hematopoietic stem cell transplant.
Authors: Boeckh M PMID: 28749913 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Identifying patients with leukemia who are at risk for fungal infections.
Authors: Bhatt VR PMID: 28749914 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/onc news.
Authors: Schuyler D PMID: 28749915 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Authors: PMID: 28749916 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The microbiome: a basis for novel immunomodulation in mice and men.
Authors: Zarour HM PMID: 28749917 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
Authors: Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI Abstract Urothelial cancer, which is predominantly seen in men, is common throughout the world. Most disease presents as non-muscle invasive bladder cancer (NMIBC), with cancer recurring or progressing to muscle invasive disease in more than 50% of patients after initial therapy. NMIBC is an immune responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. The advent of T-cell checkpoint inhibitors, especially those directed at programmed death 1 (PD-1) and its ligand (PD-L1), ...
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Authors: Wells J, Jain N, Konopleva M Abstract Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile similar to that of Ph-positive ALL; however, the BCR-ABL1 fusion is not present. The World Health Organization classification of myeloid neoplasms and acute leukemia recently was updated to include the Ph-like or BCR-ABL1-like ALL subtype of B-cell ALL as a provisional entity. Unlike Ph-positive ALL, which is characterized by the pathognomonic BCR-ABL1 fusion, Ph-like ALL is characterized by a ...
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Authors: Iyer R, Phan AT, Boudreaux JP Abstract Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that originate in the gastrointestinal system. GEP-NETs are typically indolent, but tumors known as "functional" secrete hormones that can lead to a complex of symptoms, including flushing, diarrhea, bronchospasm, and valvular heart disease. Management of patients with GEP-NETs requires a multidisciplinary approach, as treatment modalities include surgery, radiology, and pharmacotherapy. The available pharmacologic agents have increased in recently, and now include cytotoxic chemot...
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Authors: Iyer R PMID: 28654023 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Authors: Phan AT PMID: 28654024 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Surgical approaches for patients with gastroenteropancreatic nuroendocrine tumors.
Authors: Boudreaux JP PMID: 28654025 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion.
Discussion. Clin Adv Hematol Oncol. 2017 Apr;15 Suppl 4(4):18-19 Authors: Iyer R, Phan AT, Boudreaux JP PMID: 28654026 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in ovarian cancer from the 2017 Society of Gynecologic Oncology annual meeting on women's cancer.
Authors: PMID: 28654027 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in ovarian cancer from the 2017 Society of Gynecologic Oncology annual meeting on women's cancer: Commentary.
Authors: Herzog T PMID: 28654028 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Thyroid carcinoma: epidemiology, histology, and diagnosis.
Authors: Shah JP PMID: 26430868 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 15, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Local treatment of differentiated thyroid carcinoma.
Authors: Clayman GL PMID: 26430869 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 15, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
Authors: Wirth LJ PMID: 26430870 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 15, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New and emerging therapeutic options for thyroid carcinoma: A & A discussion.
New and emerging therapeutic options for thyroid carcinoma: A&A discussion. Clin Adv Hematol Oncol. 2015 04;13(4 Suppl 4):17 Authors: Clayman GL, Wirth LJ PMID: 26430871 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 15, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 2016 American Society of Hematology annual meeting and exposition.
Authors: PMID: 28590457 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 2016 American Society of Hematology meeting: Commentary.
Authors: Mesa RA PMID: 28590458 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 2016 American Society of Hematology annual meeting and exposition.
Authors: PMID: 28590459 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 2016 American Society of Hematology annual meeting and exposition: Commentary.
Authors: Horwitz SM PMID: 28590460 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition.
Authors: PMID: 28590461 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary.
Authors: Fowler NH PMID: 28590462 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Buyer Beware!
Authors: Kahl BS PMID: 28591088 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in understanding glucocorticoid receptor function in cancer.
Authors: Conzen SD PMID: 28591089 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Common fungal infections in patients with leukemia.
Authors: Wang ES PMID: 28591090 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Antifibrinolytic agents in acquired bleeding disorders.
Authors: Walsh M PMID: 28591091 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of radiation therapy in upper gastrointestinal cancers.
Authors: Ilson DH Abstract Upper gastrointestinal cancers are common and account for a high proportion of cases of cancer-related morbidity and mortality. Combined-modality therapy with surgery, chemotherapy, and radiation therapy is standard treatment for esophageal and gastroesophageal junction cancers. For gastric cancer, the need to include radiation therapy appears to depend on the quality of the surgery performed. Radiation therapy plays an uncertain role in the surgical management of pancreatic cancer, and the results of ongoing clinical trials are awaited. Retrospective studies support the inclusion of radi...
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Testicular cancer update.
Authors: Adra N, Einhorn LH Abstract The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the collaborative efforts of cancer researchers around the world. Investigators have been able to address many questions regarding the treatment of patients with disease limited to the testis, those with metastasis to the retroperitoneum only, and those with advanced metastatic disease. Questions answered include the chemotherapeutic agents to be used and in what combinations, the proper intensity of treatment and appropriate dosing, t...
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
Authors: Malouf GG, Joseph RW, Shah AY, Tannir NM Abstract The non-clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and exhibits a distinct clinical behavior and response to therapy. The advent of next-generation sequencing has drastically advanced our understanding of key genetic and epigenetic drivers in these tumors, although mechanistic studies are needed to elucidate pathogenesis. The only 2 randomized clinical trials in nccRCC included patients with diverse histologic subtypes. Both of these trials compared everolim...
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Affordable Care?
Authors: Kahl BS PMID: 28591095 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Genetic conditions associated with a predisposition to kidney cancer.
Authors: PMID: 28591096 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The best treatments to use after checkpoint inhibition in melanoma.
Authors: McArthur G PMID: 28591097 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of CAR T cells in diffuse large B-cell lymphoma and mantle cell lymphoma.
Authors: Martin P PMID: 28591098 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Antibody-drug conjugates in breast cancer.
Authors: Bardia A PMID: 28591100 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of patients with carcinoid syndrome.
Authors: Kulke MH PMID: 28591101 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How direct-to-patient research can improve interest in clinical trials.
Authors: Collyar D PMID: 28591102 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment of acute lymphoblastic leukemia in older adults: now and the future.
Authors: Yilmaz M, Kantarjian H, Jabbour E Abstract Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, the mortality rate is unacceptably high. The 5-year survival rate for patients achieving a remission ranges from 17% to 23%. ALL is usually more aggressive in older patients, and these patients' reduced functional capacity renders them less able to tolerate treatment. The need for less-intensive, more-efficient treatment modalities in this population of frail and high-risk patients is evide...
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Myeloma bone disease: pathogenesis and treatment.
Authors: O'Donnell EK, Raje NS Abstract Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in nearly 90% of patients with MM, and these are frequently complicated by skeleton-related events (SREs) such as severe bone pain, pathologic fractures, vertebral collapse, hypercalcemia, and spinal cord compression. SREs have a negative effect on patients' quality of life and affect their long-term outcomes, including survival. In MM, the delicate balance between bone formation and bone destruction is perturbed. OBD...
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Everything old is new again: the case for imatinib as frontline therapy in 2017.
Authors: Lee SG, Lipton JH PMID: 28591105 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The biology of CML supports second-generation TKIs as frontline treatment.
Authors: Fava C, Saglio G PMID: 28591106 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 8, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: When will we beat R-CHOP?
Authors: Kahl BS PMID: 28398269 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Authors: Shapiro GI PMID: 28398270 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research